Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 2 1

Status

Not yet recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Colorectal Neoplasms 317Rectal Neoplasms 235Stomach Neoplasms 209Pancreatic Neoplasms 137Colonic Neoplasms 94Neoplasm Metastasis 60Esophageal Neoplasms 57Neoplasms 40Biliary Tract Neoplasms 39Cholangiocarcinoma 31Carcinoma, Hepatocellular 30Gallbladder Neoplasms 29Breast Neoplasms 28Adenocarcinoma 22Bile Duct Neoplasms 21Locally Advanced Rectal Cancer 20Adenocarcinoma Of Esophagus 20Gastrointestinal Neoplasms 18Liver Neoplasms 17Esophageal Squamous Cell Carcinoma 17Colorectal Cancer Metastatic 15Carcinoma, Non-Small-Cell Lung 12Anus Neoplasms 12Parkinson Disease 4, Autosomal Dominant Lewy Body 11Digestive System Neoplasms 7Carcinoma 7Advanced Gastric Cancer 7Squamous Cell Carcinoma of Head and Neck 6Ovarian Neoplasms 6Klatskin Tumor 6

Interventions

Trastuzumab 5Oxaliplatin 4Capecitabine 3trastuzumab deruxtecan 2tislelizumab 2disitamab vedotin 2Tegafur 2Fluorouracil 2Cisplatin 2tucatinib 1pembrolizumab 1S 1 (combination) 1Ramucirumab 1Paclitaxel 1HMPL-013 1Drug Therapy 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
HER2-positive Gastric Cancer × Capecitabine × Gastrointestinal × Clear all
NCT06764875 2026-05-12

A Phase â…¢ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

AstraZeneca

Phase 3 Recruiting
840 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

NCT07332533 2026-01-12

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

Shanghai JMT-Bio Inc.

Phase 2/3 Not yet recruiting
490 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

NCT06998771 2025-05-31

JSKN003 Combined Treatment of HER2-positive Gastric Cancer

Shanghai JMT-Bio Inc.

Phase 2 Not yet recruiting
153 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡